Global Molecular Information Systems Market Overview:
A molecular information system is often used to determine the sequence in DNA or genetic material, enzymes, proteins at the molecular level using kits, reagents, and instruments. Various methods are used to determine the sequence in molecular information, including the use of instruments such as PCR, RAPD, and DNA microarrays. Molecular information systems are beneficial in a variety of medical strengths including infectious diseases, oncology, human leukocyte antigens typing and coagulation, and pharmacogenomics. The impact of COVID-19 on digital solutions in terms of healthcare delivery has been and is very high and accelerating as fast as COVID-19 moves around the world. There are many lessons to be learned from the use of technology in public health monitoring, from linking data in Sentinel laboratories to developing technological solutions to instantly link tests in different geographic locations.
- Increase in Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
- High Prevalence of Infectious Diseases and Various Types of Cancers
- Increasing Demand for Point-Of-Care Diagnostics
- Strict Regulatory and Legal Requirements Related To the System
- Need For high-complexity Testing Centers
- The Growing Advances in Genomics and Proteomics
- Rising Usage of Well-Established Technologies, Such As Immunoassays
- Delay in Approval of New Molecular Information
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Abbott Laboratories (United States), Agilent Technologies Inc. (United States), Biomerieux SA (France), Becton, Dickinson, and Company (United States), Danaher Corporation (United States), F.Hoffmann-La Roche (Switzerland), Hologic Inc. (United States), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (United States), DiaSorin S.p.A. (Italy) and Luminex Corporation (United States). Additionally, following companies can also be profiled that are part of our coverage like Molbio Diagnostics Pvt. Ltd. (India) and geneOmbio Technologies Pvt. Ltd. (India). Analyst at AMA Research see United States Players to retain maximum share of Global Molecular Information Systems market by 2026. Considering Market by Technology, the sub-segment i.e. Polymerase Chain Reaction (PCR) will boost the Molecular Information Systems market. Considering Market by End User, the sub-segment i.e. Hospital & Academic Laboratories will boost the Molecular Information Systems market.
Latest Market Insights:
In January 2021, Hologic Inc. had acquired Biotheranostics Inc. for expanding its molecular diagnostics portfolio. and In May 2020, Roche Diagnostics had acquired Stratos Genomics so as to complement the development of its nanopore technology and thereby gave access to Stratos Genomic's unique chemistry, Sequencing by Expansion (SBX).
In March 2020, Abbott Laboratories had launched the ID NOW PoC testing system.
The FDA has emphasized that it has regulatory authority over LDTs (laboratory-developed tests) but has chosen to exercise some enforcement discretion on such tests. In recent years, however, the FDA has stated that additional monitoring of LDTs is required and that the agency plans to issue a guidance document on it. Even issuing the draft directive will therefore certainly raise questions and create new problems.
What Can be Explored with the Molecular Information Systems Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Molecular Information Systems Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Molecular Information Systems
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Molecular Information Systems market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Molecular Information Systems market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Molecular Information Systems, Venture Capitalists and Private Equity Firms and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.